Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > REGULATORY
REGULATORY
- 5 Wholesalers Ordered to Pay 627 Million Yen in Surcharge over Kyushu Bid-Rigging
March 27, 2023
- Public Comments 2 to 1 in Favor of Approving Abortion Pill: MHLW
March 27, 2023
- MHLW to Review Application of Emergency Approval System after COVID Downgrade
March 27, 2023
- Expert Panel Proposal to Be Discussed Outside Chuikyo Too as Needed: Health Minister
March 27, 2023
- Japan Marks Record Low of New HIV, AIDS Cases in 20 Years in 2022
March 27, 2023
- Japan Grants Sakigake Designation to Satralizumab, Lu AF82422
March 27, 2023
- MHLW to Resume Discussions on Revising Basic Immunization Plan
March 27, 2023
- Review of Abortion Pill Postponed amid Flock of Public Comments
March 24, 2023
- Xocova to Be Commercially Available from March 31
March 24, 2023
- Additional Safety Measures for Xocova “Not Needed at This Time”: MHLW Panel
March 24, 2023
- MHLW Orders Label Revisions for TB Drugs, Steboronine
March 24, 2023
- Japan to Designate 3 More Diseases as Intractable Illnesses
March 24, 2023
- MHLW Panel Begins Discussions on Revision of Basic Policy for Blood Products
March 23, 2023
- Generic Dispensing Tops 82%; 57% of Pharmacies Not Active on Biosimilars: Poll
March 23, 2023
- Chuikyo’s SaMD Working Group to Compile Opinion by July
March 23, 2023
- Majority of Pharmacists Think Setting Up Integrated Drug Supply Website Is Vital: MHLW Study
March 22, 2023
- Japan to Tap Patient-Initiated Mixed Care Scheme for Pediatric Cancer Meds
March 22, 2023
- MHLW Council Discusses Root Causes of Drug Supply Disruptions, Yakkasa Issues
March 22, 2023
- MHLW Panel OKs 184 More Health Damage Claims for COVID-19 Jabs
March 22, 2023
- Japan Approves J-TEC’s Cell Sheet for Vitiligo, Aurion’s Bullous Keratopathy Therapy
March 22, 2023
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…